Target Price | $579.51 |
Price | $521.63 |
Potential | 11.10% |
Number of Estimates | 25 |
25 Analysts have issued a price target Intuitive Surgical 2026 . The average Intuitive Surgical target price is $579.51. This is 11.10% higher than the current stock price. The highest price target is $675.00 29.40% , the lowest is $440.00 15.65% . | |
A rating was issued by 34 analysts: 20 Analysts recommend Intuitive Surgical to buy, 12 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Intuitive Surgical stock has an average upside potential 2026 of 11.10% . Most analysts recommend the Intuitive Surgical stock at Purchase. |
27 Analysts have issued a sales forecast Intuitive Surgical 2025 . The average Intuitive Surgical sales estimate is $9.7b . This is 10.93% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $9.8b 12.81% , the lowest is $9.5b 8.99% .
This results in the following potential growth metrics:
2024 | $8.4b | 17.24% |
---|---|---|
2025 | $9.7b | 15.75% |
2026 | $11.1b | 15.33% |
2027 | $12.9b | 15.50% |
2028 | $14.4b | 11.78% |
2029 | $16.0b | 10.84% |
21 Analysts have issued an Intuitive Surgical EBITDA forecast 2025. The average Intuitive Surgical EBITDA estimate is $3.9b . This is 59.77% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $4.8b 95.52% , the lowest is $3.3b 34.70% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $2.8b | 59.71% |
---|---|---|
2025 | $3.9b | 38.33% |
2026 | $4.5b | 15.46% |
2027 | $5.4b | 19.37% |
2028 | $6.2b | 13.27% |
2029 | $7.2b | 16.59% |
2024 | 34.11% | 36.23% |
---|---|---|
2025 | 40.76% | 19.51% |
2026 | 40.80% | 0.10% |
2027 | 42.17% | 3.36% |
2028 | 42.73% | 1.33% |
2029 | 44.95% | 5.20% |
12 Intuitive Surgical Analysts have issued a net profit forecast 2025. The average Intuitive Surgical net profit estimate is $2.5b . This is 0.14% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.7b 8.12% , the lowest is $2.3b 5.92% .
This results in the following potential growth metrics and future Net Margins:
2024 | $2.3b | 29.18% |
---|---|---|
2025 | $2.5b | 6.46% |
2026 | $2.9b | 18.74% |
2027 | $3.5b | 18.36% |
2028 | $4.1b | 16.70% |
2024 | 27.81% | 10.18% |
---|---|---|
2025 | 25.58% | 8.01% |
2026 | 26.33% | 2.93% |
2027 | 26.99% | 2.51% |
2028 | 28.17% | 4.37% |
12 Analysts have issued a Intuitive Surgical forecast for earnings per share. The average Intuitive Surgical EPS is $6.90 . This is 1.62% higher than earnings per share in the financial year 2024. The highest EPS forecast is $7.47 10.01% , the lowest is $6.50 4.27% .
This results in the following potential growth metrics and future valuations:
2024 | $6.42 | 27.63% |
---|---|---|
2025 | $6.90 | 7.48% |
2026 | $8.19 | 18.70% |
2027 | $9.70 | 18.44% |
2028 | $11.32 | 16.70% |
Current | 76.82 | 2.14% |
---|---|---|
2025 | 75.61 | 1.58% |
2026 | 63.68 | 15.78% |
2027 | 53.80 | 15.52% |
2028 | 46.10 | 14.31% |
Based on analysts' sales estimates for 2025, the Intuitive Surgical stock is valued at an EV/Sales of 18.86 and an P/S ratio of 19.34 .
This results in the following potential growth metrics and future valuations:
Current | 20.92 | 3.10% |
---|---|---|
2025 | 18.86 | 9.85% |
2026 | 16.35 | 13.29% |
2027 | 14.16 | 13.42% |
2028 | 12.67 | 10.54% |
2029 | 11.43 | 9.78% |
Current | 21.45 | 2.33% |
---|---|---|
2025 | 19.34 | 9.85% |
2026 | 16.77 | 13.29% |
2027 | 14.52 | 13.42% |
2028 | 12.99 | 10.54% |
2029 | 11.72 | 9.78% |
Intuitive Surgical...
Analyst | Rating | Action | Date |
---|---|---|---|
Deutsche Bank |
Hold
➜
Sell
|
Downgrade | Jun 09 2025 |
Citigroup |
Buy
➜
Buy
|
Unchanged | May 22 2025 |
Barclays |
Overweight
➜
Overweight
|
Unchanged | Apr 24 2025 |
Baird |
Outperform
➜
Outperform
|
Unchanged | Apr 23 2025 |
Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Apr 23 2025 |
RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Apr 23 2025 |
Evercore ISI Group |
In-Line
➜
In-Line
|
Unchanged | Apr 23 2025 |
Analyst Rating | Date |
---|---|
Downgrade
Deutsche Bank:
Hold
➜
Sell
|
Jun 09 2025 |
Unchanged
Citigroup:
Buy
➜
Buy
|
May 22 2025 |
Unchanged
Barclays:
Overweight
➜
Overweight
|
Apr 24 2025 |
Unchanged
Baird:
Outperform
➜
Outperform
|
Apr 23 2025 |
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Apr 23 2025 |
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Apr 23 2025 |
Unchanged
Evercore ISI Group:
In-Line
➜
In-Line
|
Apr 23 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.